Wed, Oct 22, 2014, 12:27 AM EDT - U.S. Markets open in 9 hrs 3 mins


% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

archijim 7 posts  |  Last Activity: 8 hours ago Member since: Jan 5, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Dr. Mauro's package.

    by aoutdoors562000 16 hours ago

    Just Google Dr. David Mauro Merck and read. This individual helped develop PD-1 at know...their next blockbuster. In August and Sept he helped pound the pavement and establish the Merck/Advaxis partnership with ADXS-PSA in trials for prostate cancer. For example:

    Health-news: "For instance, Merck is working with small biotechnology firm Advaxis, whose experimental immuno-oncology drug ADXS-PSA could be used individually or together with pembrolizumab to treat advanced prostate cancer. Skin and prostate cancers are the most common in men, so Merck could be killing two huge birds with a single stone. PD-1 drugs have not been widely tested for prostate cancer, but Merck executive director of oncology David Mauro thinks “this combination gives us the opportunity to do early exploration in prostate cancer and bring immuno-oncology into this space.” Merck is otherwise not studying pembrolizumab in combination with its own experimental drugs, though."

    And of course, the James Sheppard write up in lift stream:
    Authored by James Sheppard

    "The global pharmaceutical giant Merck & Co announced it had partnered with the New Jersey based biotech company Advaxis. The collaboration will see the pair test experimental immuno-oncology drug in combination with a high-profile immunotherapy drug from Merck for a treatment for advanced prostate cancer.

    Daniel O’Connor, CEO of Advaxis said ‘If the combination of drugs shows an added effect, the companies WOULD LIKELY CONTINUE THEIR COLLABORATION.’ David Mauro, Executive Director of Oncology at Merck added, ‘PD-1 inhibitors and other immuno-oncology drugs have already shown promise against other types of cancer, including melanoma, but have not yet been tested to any great extent against prostate cancer.’"

    All cap emphasis mine. They didn't just continue, they bought the guy....think about it...

  • archijim archijim Oct 8, 2014 10:21 AM Flag

    "Currently he is a senior investigator and Chief of Cancer Vaccine Section at the NCI, he also serve as a Special Assistant to the Commissioner of the Food and Drug Administration leading the Critical Path Initiative for oncology. "

    ASCI website. Very interesting....

  • Reply to

    Marlin Sams selling in low $9s

    by chrisnoore2525 Sep 17, 2014 6:08 AM
    archijim archijim Sep 17, 2014 10:05 AM Flag

    Disturbing to see large holders selling here. But still has 640000 shares

  • archijim by archijim Sep 11, 2014 9:54 AM Flag

    Yearly revenue more than double market cap. Cash of over $6/sh. Takeover candidate from big retailer such as Amazon. Only thing missing is profit, which seems to be coming. Langone invested personally and heavily. Management quality? Is this the bottom? I think we may be seeing it put in an historic bottom here.

  • archijim archijim Sep 10, 2014 4:44 PM Flag

    "Better as per recent rial data" I read as better for Provenge as Xtandi allowed a sustained anti-immune response. This however, does not mean a better result for survival, etc..

  • archijim archijim Sep 10, 2014 4:12 PM Flag

    Xtandi just approved for expanded label Pre-chemo use. Real question: how does Xtandi prechemo compare to Xtandi/Provenge combo Pre-chemo?

  • Reply to

    It's done.. Loosing a lot on this POS

    by magicleverage Sep 4, 2014 11:21 AM
    archijim archijim Sep 4, 2014 1:31 PM Flag

    If I read the purchase agreement correctly, the $30M would require issuance of equivalent of 42.5mil shares common which is a 55% dilution to current outstanding shares. Is that what is being priced in currently or is the stock headed to $.27 after the deal is made? I see no benefit to NSPH to compel share purchase at this time, it's as if they would be selling the majority holdings of the company with the share price so low. I'm on the fence thinking of buying in, but will wait out until I understand this issue better....

8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.